55results about How to "Uniform release rate" patented technology

The invention relates to fields of a drug for treating a disease of cari oris mucosa, and preparation thereof, and particularly relates to a mouth mucosa sustained-release preparation for treating oral and periodontal diseases by chlorhexidine. The preparation is composed of a mouth mucosa contact layer and a non-adhesive seal layer; the mouth mucosa contact layer comprises the components of an antibiotic drug and an auxiliary material, of which the weight ratio is (2-20) to (80-98); the non-adhesive seal layer comprises the components of a non-adhesive low-water soluble high-molecular polymer; the non-adhesive low-water soluble high-molecular polymer is selected from polyving akohol; the mouth mucosa sustained-release preparation comprises the components of 4.0g of chlorhexidine, 12.0g of hydroxyethyl cellulose, 5.5g of modified starch, 7.0g of microcrystalline cellulose, 0.5g of grape essence and the balance of polyving akohol. The mouth mucosa sustained-release preparation has the advantages of being convenient to drug delivery, long in drug release time, even in drug release speed, strong in target, strong in mucosa adhesive force and the like; and the preparation method is simple to operate, low in cost, friendly to environment, and suitable for industrial production.

The invention relates to an oral mucosa medicament slow release preparation for treating oral periodontal disease, which comprises an oral mucosa contact layer and an unbonded close layer, wherein the oral mucosa contact layer comprises the components of anti-biotic medicines and accessories in weight proportion of 2-20:80-98; and the unbonded close layer comprises an unbonded low water-solubility high molecular polymer. The preparation comprises the following steps: preparing a corresponding contact layer paster and water solution through uniformly mixing the anti-biotic medicine and the accessories; coating water solution of the unbonded low water-solubility high molecular polymer on a single surface of the contact layer paster; and drying to obtain the oral mucosa medicament slow release preparation. The oral mucosa medicament slow release preparation has convenient administration, long medicament release, uniform release speed, strong target property, strong bonding property with membrane, and the like; meanwhile, the preparation method has simple operation, low cost and environment protection, and is suitable to industrialized production.

The invention discloses an embedding method for oxytocin based on squid cuttlebone. Firstly, placing squids into a narcotic, and performing anaesthetization; and then embedding an oxytocin low-release agent into the cuttlebone. The method has the beneficial effects that the embedded oxytocin is located in calcareous cuttlebone of the squids, thus the embedded oxytocin has small stimulation effects on the squids, the cuttlebone has a loose and porous structure, and therefore the oxytocin can be easily released into bodies to play roles; and a certain amount of L-medetomidine is added to R-medetomidine, thus the prepared narcotic has long anaesthetization hold time and a certain analgesic effect, the stress reaction of the squids to an embedding process is greatly reduced, and ink spraying is avoided; and the GnRH low-release agent prepared by using chitosan quaternary ammonium salt as a carrier has good biocompatibility, long release time and a uniform release speed.

The invention relates to drugs for treating mouth mucosa diseases and the manufacture field of the drugs for treating mouth mucosa diseases, in particular to a mouth mucosa drug sustained release preparation for treating a mouth periodontal disease by doxycycline. The preparation is composed of a mouth mucosa contacted layer and a non-adhesiveness sealing layer. The mouth mucosa contacted layer comprises, by weight, 2-20 / 80-98 of antibiotic drugs and auxiliary materials. The components of the non-adhesiveness sealing layer are non-adhesiveness low water-solubility high-molecular polymers. The non-adhesiveness low water-solubility high-molecular polymers are chosen from polyvinyl alcohol. The components of mouth mucosa drug sustained release preparation comprise 2.0g of methyl vinyl ether-maleic anhydride copolymers, 2.0g of polyoxyethylene, 2.0g of carboxymethyl cellulose sodium, 12.0g of natural starch, 2.0g of menthol and 0.5g of doxycycline, and the rest is poval. The mouth mucosa drug sustained release preparation has the advantages that drug delivering is convenient, drug releasing time is long, drug releasing speed is even, targeting is strong, and adhesive force with mucosas is strong. In addition, the manufacturing method is simple in operation, low in cost, environment-friendly and suitable for industrial production.

The invention relates to a felodipine sustained-release tablet, wherein the percentages of raw and auxiliary materials of the sustained-release tablet in the total weight of the tablet core are: 1%-5%of felodipine, 30-80% of matrix material, 1-20% of filler, 1-10% of solubilizer, 10-30% of excipient, 1-10% of adhesive and 0.01-0.1% of antioxidant.